Beyond acquisitions, we continue to expect steady future dividends, supported by a payout ratio of close to 50% relative to adjusted earnings per share. Patents, economies of scale, and a powerful ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...

A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a ...

Kiran Mazumdar-Shaw accompanied her niece in ringing the opening bell at the Nasdaq headquarters in New York City, marking a ...

Silicon Valley accelerator Y Combinator held the second Demo Day for its Summer 2024 cohort on Thursday, and just like we saw ...

By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...

Awardees were recognized for developing renewable lubricant base oils and ethyl acetate, more environmentally-friendly ...

It’s similar with multiple sclerosis. Actually, there are so many good drugs out there. A lot of the market has already been ...